Skip to main content

Advertisement

Table 3 SMFA results for Pfs230C1 and Pfs230D1+ as tested in two immunization studies

From: The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate

NameConc [μg/mL]Mean oocyst%TRA(95% CI)p-value
Immunization study #1
 Control750.010.9   
 C1 (5.0)750.00.298.2(95 to 100)0.001
 C1 (0.5)750.00.298.2(95 to 100)0.001
 C1 (0.05)750.01.784.9(65 to 94)0.001
 D1+ (5.0)750.00.298.2(95 to 100)0.001
 D1+ (0.5)750.00.298.2(95 to 100)0.001
 D1+ (0.05)750.00.496.8(92 to 99)0.001
Immunization study #2
 Control750.039.2   
 C1 (1.0)750.00.598.9(97 to 100)0.001
 D1+ (1.0)750.00.199.7(99 to 100)0.001
  1. Purified IgG samples were tested at 750 μg/mL by SMFA with complement. Mean oocyst number, % reduction of oocyst density (%TRA), the 95% confidence interval, and p-value of each test IgG are shown